SUMMARY The anticonvulsant drug phenytoin has several interesting immunological properties which could theoretically be of benefit in the treatment of rheumatoid arthritis. For this reason a pilot study has been carried out on 11 patients with active classical or definite disease. Seven patients completed a 20 week course of treatment and showed continuous improvement at 12 and 20 weeks and some deterioration eight weeks after the drug was stopped. Laboratory and clinical measurements of disease activity responded favourably during the treatment period, suggesting that phenytoin may have second line activity.
Rheumatoid arthritis (RA) is an immunologically mediated disease characterised by erosive destruction of joints. As a consequence, effective forms of therapy often involve the induction of immunosuppression. Phenytoin, one of the hydantoin group of anticonvulsants, has many interesting immunological properties such as production of selective IgA deficiency,' the induction of spontaneous suppressor T cell activity, and thus antibody deficiency, and occasional induction of We believe from the data acquired during this pilot study that phenytoin may be such a drug, and we are now comparing it in a double blind controlled trial with the standard second line drug penicillamine.
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